The broad spectrum of options for therapeutic targeting of RNA has attracted substantial interest from both academic research institutes and pharmaceutical companies. With a growing number of approved RNA therapeutics now generating significant profits, the level of investment in the field has grown. In this article, we analyse investment data for companies developing RNA therapeutics and their pipelines.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
J.K.W. is an ad hoc consultant or has received seminar honoraria from Biogen, AstraZeneca, Flagship Pioneering, or The Medicines Company within the past 12 months.
